The position of combined medical treatment in acromegaly

Coopmans, Eva C; van Meyel, Sebastiaan W F; van der Lely, Aart J; Neggers, Sebastian J C M M

Coopmans, Eva C; van Meyel, Sebastiaan W F; van der Lely, Aart J; Neggers, Sebastian J C M M.

Coopmans, Eva C; Erasmus University Medical Center Rotterdam. Pituitary Center Rotterdam. Section Endocrinology. Rotterdam. hungria
van Meyel, Sebastiaan W F; Erasmus University Medical Center Rotterdam. Pituitary Center Rotterdam. Section Endocrinology. Rotterdam. hungria
van der Lely, Aart J; Erasmus University Medical Center Rotterdam. Pituitary Center Rotterdam. Section Endocrinology. Rotterdam. hungria
Neggers, Sebastian J C M M; Erasmus University Medical Center Rotterdam. Pituitary Center Rotterdam. Section Endocrinology. Rotterdam. hungria

Arch. endocrinol. metab. (Online) ; 63(6): 646-652, Nov.-Dec. 2019.

Article in English | LILACS | ID: biblio-1055016

ABSTRACT

ABSTRACT

ABSTRACT Advances in combination medical treatment have offer new perspectives for acromegaly patients with persistent disease activity despite receiving the available medical monotherapies. The outcomes of combination medical treatment may reflect both additive and synergistic effects. This review focuses on combination medical treatment and its current position in acromegaly, based on clinical studies evaluating the efficacy and safety of combined medical treatment(s) and our own experiences with combination therapy. Arch Endocrinol Metab. 2019;63(6)646-52

Subject(s)

Humans; Somatostatin/analogs & derivatives; Receptors, Somatostatin/administration & dosage; Receptors, Somatostatin/antagonists & inhibitors; Dopamine Agonists/administration & dosage; Human Growth Hormone/analogs & derivatives; Quality of Life; Acromegaly/drug therapy; Somatostatin/administration & dosage; Human Growth Hormone/administration & dosage; Drug Therapy, Combination

Acromegaly; Pasireotide; Pegvisomant; Somatostatin

Fulltext

XML

Search on Google

Full text: Available Index: LILACS (Americas) Main subject: Somatostatin / Receptors, Somatostatin / Dopamine Agonists / Human Growth Hormone Limits: Humans Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2019 Type: Article Affiliation country: Hungary Institution/Affiliation country: Erasmus University Medical Center Rotterdam/hungria

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google